The Institute of Experimental Medicine, with the support of the Russian Science Foundation, is in the process of developing a combined influenza and coronavirus vaccine that activates T-cell immunity.

Doctor of Biological Sciences Irina Isakova-Sivak, Head of the Laboratory of Immunology and Prevention of Viral Infections of the Federal State Budgetary Scientific Institution ‘IEM’ (head of the scientific group involved in the development) gave a long interview in which she talks about the features of the vaccine, about the choice of the direction of scientific interests, about research within the framework of grants from the Russian scientific fund.